Global Prefilled Syringes Market Size and Share Analysis 2023-2028
- 시장 보고서
- ID: KHA810GM
- 배달 시간: 1 영업일
- 꼬리표: Prefilled Syringes
시장 개관
The prefilled syringes market was valued at USD 7.2 billion in the base year and is projected to grow at a CAGR of 10.69% 예측 기간 동안.
The global prefilled syringes market experienced a positive impact from the COVID-19 pandemic, as these syringes were widely used for COVID-19 vaccines. The pandemic accelerated the development of prefilled syringes, particularly for vaccines requiring low-temperature storage. 예를 들어, 9월 2021, 벡톤, Dickinson, and Company (BD) demonstrated the suitability of their glass prefilled syringes for mRNA COVID-19 vaccines that require ultralow temperature storage. The company highlighted that switching from vials to prefilled syringes can address the cost and complexity of vaccine administration. 따라서, the outbreak of COVID-19 in 2020 led to increased sales of prefilled syringes globally.
상품 유형 | 시장 조사 |
---|---|
페이지 | 148 |
출시일 | 3월 2023 |
기준 연도 | 2022 |
예측기간 | 2023-2028 |
시장 규모 | 미화 7.2 10억 2021 |
시장 부문 | 재료, 유형, 애플리케이션, 지역 |
지역 | 글로벌 |
아니요. 언급된 회사 수 | 10 |
The market growth is primarily driven by the rising demand for efficient and user-friendly drug delivery devices, as well as the healthcare industry’s focus on reducing errors in hospital settings. Technological advancements have facilitated the development of feature-rich devices that enhance the safety and convenience of self-injection for patients. 뿐만 아니라, the impact of COVID-19 and the need for convenient drug delivery methods have contributed to the growth of the prefilled syringes market.
Prefilled syringes have gained popularity as a preferred option for unit-dose medication, as the pharmaceutical industry seeks more convenient drug delivery methods. Self-injectable contraception, 예를 들어, has been recognized by the World Health Organization as a self-care intervention that can reduce unintended pregnancies. The organization estimates that individuals spend less than one hour per year with healthcare professionals but over 8700 hours practicing self-care. The increasing adoption of self-care practices is expected to drive the demand for prefilled syringes and fuel market growth.
게다가, the increasing prevalence of diseases such as diabetes and rheumatoid arthritis, along with the growing adoption of biosimilars in developed regions, will further propel market expansion. According to a report by SingleCare in January 2022, 이상 14.0 million people worldwide suffer from rheumatoid arthritis annually, 이상으로 1.36 million cases in the United States alone. Rheumatoid arthritis is the most common form of autoimmune arthritis in the US, affecting approximately 0.6% 에게 1.0% of the population each year. As prefilled syringes offer safety at an affordable price, their usage is expected to increase in the future.
추가적으로, the introduction of new products will actively contribute to market growth. 5월 2022, Terumo Corporation launched a prefillable polymer syringe for low-dose applications, providing a safe and effective treatment option. Government investments in advanced syringe production will also drive market growth. 예를 들어, 3월 2022, Hungary invested USD 84.53 million to expand prefillable glass syringe production, aiming to meet the growing global demand. The expansion project is expected to be completed by 2024 and will support the market’s future demand.
하지만, product recalls and the availability of alternative drug delivery methods are factors that may hinder market growth.
시장 세분화
시장은 다양한 요인에 따라 분류됩니다., 재료를 포함하여, type, 애플리케이션, 및 지역.
재료별 세분화
Glass Prefilled Syringe
Plastic Prefilled Syringe
유형별 세분화
With Needle
Without Needle
애플리케이션 별 세분화
당뇨병
Anaphylaxis
Rheumatoid Arthritis
종양학
기타 애플리케이션
지역별 세분화
북아메리카 – 미국, 캐나다, 그리고 멕시코
유럽 – 영국, 독일, 프랑스, 스페인, 이탈리아, 및 유럽의 나머지 지역
아시아 태평양 – 중국, 일본, 인도, 대한민국, 호주, 및 기타 아시아 태평양 지역
라틴 아메리카 – 브라질, 아르헨티나, 및 나머지 라틴 아메리카
중동 및 아프리카 – 남아프리카, GCC, 및 기타 중동 및 아프리카
~ 안에 2022, the glass prefilled syringes segment dominated the market with a share of USD 4,666 백만. CAGR로 성장할 것으로 예상됩니다. 9.24% 예측 기간 동안. The increasing demand for glass prefilled syringes can be attributed to their numerous advantages. These syringes are designed to safely deliver drugs or biologics to patients. They can be connected to various devices such as needles, IV lines, adapters, and transfer units. Glass prefilled syringes improve patient safety by reducing the risk of accidental needle sticks and exposure to toxic substances when drawing medication from vials. 추가적으로, the premeasured dosages in these syringes help reduce dosing errors and enhance patient compliance.
The with needle segment held the largest share in the market, amounting to USD 3,946 백만 단위 2022. It is expected to grow at a CAGR of 10.31% 예측 기간 동안. Prefilled syringes with needles are commonly used for biological and pharmaceutical drug products. Multidose vial needle-prefilled syringes provide basic protection and ease of use, while single-dose prefilled syringes and passive safety devices offer enhanced safety, convenience, and flexibility. The growing use of needle-prefilled syringes is a key factor driving the growth of this segment. 추가적으로, the increasing prevalence of diseases such as cancer, cardiovascular disease, ophthalmic disorders, neurological disorders, and autoimmune diseases also contribute to the segment’s growth.
The diabetes segment held the largest share in the market, USD 도달 2,623 백만 단위 2022. It is expected to grow at a CAGR of 11.53% 예측 기간 동안. The dominance of the diabetes segment is primarily due to the rising cases of diabetes worldwide. Diabetes is a chronic disease that occurs when the pancreas fails to produce insulin or when the body cannot effectively use the insulin it produces. Prefilled syringes are widely used by diabetes patients for multiple insulin doses. Factors such as a large patient base, increasing prevalence of diabetes, and the need for effective and safe insulin delivery devices contribute to the continued dominance of this segment throughout the forecast period.
The increasing prevalence of diabetes globally is a major driver for market expansion. Diabetes is a significant public health issue that poses threats to public health and socioeconomic development. According to the International Diabetes Federation (IDF), 약 537 million adults between the ages of 20 그리고 79 were living with diabetes in 2021. The IDF projects that the number of individuals with diabetes will increase to 63 백만 단위로 2030 그리고 783 백만 단위로 2045.
Major companies like BD are developing prefilled syringes specifically for chronic disease treatment to strengthen their market position. 예를 들어, 5월 2021, BD announced plans to spin off its Diabetes Care division into a separate publicly-traded company called NewCo. BD Diabetes Care plays a significant role in the adoption of insulin syringes and other products, catering to approximately 30 million patients and producing around 8 billion injection devices annually. Such factors are expected to drive the demand for prefilled syringes in the foreseeable future.
뿐만 아니라, 3월 2022, Novo Nordisk launched its smart insulin pens in the UK, providing people treated within the NHS for diabetes access to devices that can monitor and record dosing information. 비슷하게, 11 월 2020, Medtronic PLC introduced InPen integrated with real-time Guardian Connect CGM data. InPen is the first and only FDA-cleared smart insulin pen designed for individuals on multiple daily injections (MDI). These advancements are expected to drive the growth of the corresponding segments in the market during the forecast period.
North America is anticipated to hold a significant market share throughout the forecast period due to healthcare practitioners’ strong preference for prefilled injectable devices, which helps reduce needle-related injuries. 게다가, the region is home to major market players such as Gerresheimer AG, SCHOTT group, Stevanato Group, Haselmeier AG, and Owen Mumford Ltd. These companies have established a strong presence in the region over the years. 따라서, the demand for prefilled syringes is increasing in the United States, propelling market growth.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) update in December 2020, 약 34.2 million people (10.5% of the population) had diabetes. Patients with Type 1 diabetes often require regular intravenous administration of insulin to manage their blood sugar levels. Prefilled syringes provide convenience and ease of administration for self-administration.
뿐만 아니라, innovative product launches and approvals in the United States are expected to drive market growth during the forecast period. 예를 들어, 9월 2022, BD introduced a new glass pre-fillable syringe called BD Effivax Glass PFS, which aims to set a new performance standard for vaccine PFS. This syringe was developed in collaboration with pharmaceutical companies to meet evolving vaccine manufacturing needs.
추가적으로, 10 월 2022, West Pharmaceutical Services, 주식회사. participated in the 2022 Parenteral Drug Association (PDA) Universe of prefilled syringes and Injection Devices Conference, where they presented developments in large volume delivery systems, self-injection devices, and pre-fillable syringe components. These developments are expected to contribute to market growth.
이러한 요소를 고려하여, the North American region is expected to witness promising growth in the studied market over the forecast period.
경쟁 구도
The prefilled syringes market exhibits a fragmented landscape, attributed to the presence of numerous companies. These market participants are diligently implementing various organic and inorganic growth strategies to secure a larger share of revenue within this industry. Notable companies operating in the prefilled syringes market include Becton, Dickinson, and Company, Terumo Corporation, Gerresheimer AG, SCHOTT, West Pharmaceutical Services, 주식회사, and West Pharmaceutical Services, 주식회사, 무엇보다도.
Key Companies Profiled in this report include Becton, 디킨슨 앤 컴퍼니, Gerresheimer AG, Laboratoire Aguettant, Nipro Corporation, Schott AG, Stevanato Group, Taisei Kako Co., (주), Terumo Corporation, West Pharmaceutical Services Inc., Plas-Tech Engineering, 주식회사.
최근 산업 발전
1월 2022, Owen Mumford declared the receipt of regulatory approval for its UniSafe 1mL safety device designed for pre-filled syringes in Asia. 비슷하게, 유럽에서, UniSafe 1mL has also obtained regulatory approval and is currently accessible in the market as a combination product, alongside a drug used for treating rheumatoid arthritis.
1월 2021, Aurobindo Pharma Limited received authorization from the United States Food and Drug Administration (USFDA) to produce and distribute the Naloxone HCl Injection Prefilled Syringe 2 mg/2 mL.
주요 질문에 대한 답변
What is the duration of the research period for this market study?
What is the rate of growth for the Prefilled Syringes Market?
What was the size of the Prefilled Syringes Market in 2018?
What is the projected size of the Prefilled Syringes Market in 2028?
Which region exhibits the highest growth rate in the Prefilled Syringes Market?
Which region holds the largest share in the Prefilled Syringes Market?
Who are the major players in the Prefilled Syringes Market?
미화 4,750 원래 가격은: 4,750달러.미화 2,850현재 가격은: 2,850달러.